Upstream Bio, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts. With no products approved for sale and minimal revenue, UPB operates as a single-asset firm where clinical progress and financing needs shape the equity value far more than diversified holdings would.
The lead program, verekitug, is an investigational monoclonal antibody that targets the receptor for thymic stromal lymphopoietin (TSLP). It is advancing through Phase 2 trials in severe asthma (VALIANT) and chronic rhinosinusitis with nasal polyps (VIBRANT), with earlier work underway in COPD. Management expects Phase 3 studies to begin in 2027. This narrow focus means any news on verekitug can move the entire stock sharply.
In the past 30 days, UPB shares have declined about 38%, slipping from roughly $2.80 to near $1.73. The move has followed a steady downtrend marked by elevated volume on down days rather than one discrete catalyst.
The picture looks even more pronounced over the trailing quarter. From levels near $6.85 in mid-August, the stock has fallen approximately 75%. Intermittent bounces have failed to reverse the broader de-rating.
The most recent weakness followed the third-quarter 2026 earnings release. UPB reported a net loss of $0.75 per share, wider than the consensus estimate of about $0.67, while revenue came in at roughly $0.4 million. The combination of larger losses and lower collaboration revenue highlighted ongoing cash-burn concerns.
Shortly afterward, H.C. Wainwright reduced its price target to $18 from $36 while keeping a Buy rating. That adjustment reflected tempered expectations for near-term catalysts even among supportive analysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Broader market sentiment has added pressure. Pre-revenue biotech names continue to trade at a discount in a higher-for-longer rate environment, with financing and potential dilution risks remaining front of mind for investors.
The three-month slide goes beyond a single earnings miss. Even after the VALIANT Phase 2 study in severe asthma met its primary endpoint, the market response stayed muted and shares kept declining. Several analysts trimmed targets during the period, and the stock is now down about 88% year to date from its 52-week high near $33.68.
Investor preference has shifted toward profitable, cash-flow-positive companies. Without near-term revenue, UPB relies on successful trial execution and a sufficient cash runway, leaving it exposed to repeated valuation compression.
Looking forward, attention will center on clinical milestones. Investors will track the planned start of Phase 3 trials in severe asthma and CRSwNP during 2027, additional data presentations at medical meetings, and any feedback from the FDA.
Cash management will stay in focus. With roughly $207 million in cash and short-term investments and widening operating losses, quarterly burn rates and any potential equity raises will draw scrutiny. Competition in the TSLP space, where an approved therapy already exists, means differentiation on dosing, efficacy, and safety will influence longer-term views. Trial setbacks, additional financing needs, and risk-off moves in small-cap biotech represent the main downside risks, while positive late-stage results and prudent capital allocation could support stabilization.
When evaluating volatile clinical-stage names like UPB, I often turn to Tickeron’s AI Screener to quickly compare technical patterns, fundamentals, and momentum across the sector. The platform helps surface comparable candidates and flag shifting trends that might otherwise require hours of manual review. In my view, it adds useful context when weighing single-asset stories against broader industry moves.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
UPB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 23 instances where the indicator turned negative. In 21 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UPB as a result. In 24 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for UPB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPB advanced for three days, in 85 of 103 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
UPB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.653) is normal, around the industry mean (3.596). P/E Ratio (-1.122) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology